AccScience Publishing / IJB / Volume 8 / Issue 4 / DOI: 10.18063/ijb.v8i4.616
Submit to IJB
Cite this article
25
Download
1216
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW

3D Bioprinting for Regenerating COVID-19-Mediated Irreversibly Damaged Lung Tissue

Fariya Akter1,2,3† ,  Yusha Araf4† ,  Salman Khan Promon5 ,  Jingbo Zhai6,7 ,  Chunfu Zheng1,2,8*
Show Less
1 The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University. 411643.5, Hohhot, China.
2 Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
3 Biotechnology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh
4 Department of Biotechnology Agricultural University, Mymensingh, Bangladesh
5 Department of Life Sciences, School of Environment and Life Sciences, Independent University (IUB), Bashundhara, Dhaka, Bangladesh
6 Medical College, Inner Mongolia Minzu University, Tongliao, 028000, China
7 Key Laboratory of Zoonose Prevention and Control at Universities of Inner Mongolia Autonomous Region, Tongliao, 028000, China
8 Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
IJB 2022, 8(4), 616 https://doi.org/10.18063/ijb.v8i4.616
Submitted: 29 April 2022 | Accepted: 14 July 2022 | Published: 13 September 2022
© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Correction

Correction for this article is available: view correction

Abstract

While the tension of COVID-19 is still increasing, patients who recovered from the infection are facing life-threatening consequences such as multiple organ failure due to the presence of angiotensin-converting enzyme 2 receptor in different organs. Among all the complications, death caused by respiratory failure is the most common because severe acute respiratory syndrome coronavirus 2 infects lung’s type II epithelial, mucociliary, and goblet cells that eventually cause pneumonia and acute respiratory distress syndrome, which are responsible for the irreversible lung damage. Risk factors, such as age, comorbidities, diet, and lifestyle, are associated with disease severity. This paper reviews the potential of three-dimensional bioprinting in printing an efficient organ for replacement by evaluating the patient’s condition.

Keywords
COVID-19
Irreversible heart tissue damage
Regenerative medicine
3D bioprinting
References

1. Stadler K, Masignani V, Eickmann M, et al., 2003, SARS--Beginning to Understand a New Virus. Nat Rev Microbiol, 1:209–18. https://doi.org/10.1038/nrmicro775

2. Mackay IM, Arden KE, 2015, MERS Coronavirus: Diagnostics, Epidemiology and Transmission. Virol J, 12:222. https://doi.org/10.1186/s12985-015-0439-5

3. Jin Y, Yang H, Ji W, et al., 2020, Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses, 12:372. https://doi.org/10.3390/v12040372

4. Wang C, Horby PW, Hayden FG, et al., A Novel Coronavirus Outbreak of Global Health Concern. Lancet (London, England), 395:470–3. https://doi.org/10.1016/S0140-6736(20)30185-9

5. Zhou F, Yu T, Du R, et al., 2020, Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet, 395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3

6. Yan Z, Yang M, Lai CL, 2021, Long COVID-19 Syndrome: A Comprehensive Review of its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. Biomedicines, 9:966. https://doi.org/10.3390/biomedicines9080966

7. Greenhalgh T, Knight M, A’Court C, et al., 2020, Management of Post-Acute Covid-19 in Primary Care. BMJ, 370:m3026. https://doi.org/10.1136/bmj.m3026

8. Gheblawi M, Wang K, Viveiros A, et al., 2020, Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circ Res, 126:1456-74. https://doi.org/10.1161/CIRCRESAHA.120.317015.

9. Guan W, Ni Z, Hu Y, et al., 2020, Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 382:1708–20. https://doi.org/10.1056/NEJMoa2002032

10. Hui KP, Cheung MC, Perera RA, et al., 2020, Tropism, Replication Competence, and Innate Immune Responses  of the Coronavirus SARS-CoV-2 in Human Respiratory Tract and Conjunctiva: An Analysis in ex-vivo and in-vitro Cultures. Lancet Respir Med, 8:687–95. https://doi.org/10.1016/S2213-2600(20)30193-4

11. Sungnak W, Huang N, Bécavin C, et al., 2020, SARS-CoV-2 Entry Factors are Highly Expressed in Nasal Epithelial Cells Together with Innate Immune Genes. Nat Med, 26:681–7. https://doi.org/10.1038/s41591-020-0868-6

12. Mason RJ, 2020, Pathogenesis of COVID-19 from a Cell Biology Perspective. Eur Respir J, 55:2000607. https://doi.org/10.1183/13993003.00607-2020

13. Anderson DJ, Politch JA, Nadolski AM, et al., 2010, Targeting Trojan Horse Leukocytes for HIV Prevention. AIDS, 24:163–87. https://doi.org/10.1097/QAD.0b013e32833424c8

14. Ayala-Nunez NV, Follain G, Delalande F, et al., 2019, Zika Virus Enhances Monocyte Adhesion and Transmigration Favoring Viral Dissemination to Neural Cells. Nat Commun, 10:4430. https://doi.org/10.1038/s41467-019-12408-x

15. Hu Y, Zhan C, Chen C, et al., 2020, Chest CT Findings Related to Mortality of Patients with COVID-19: A Retrospective Case-Series Study. PLoS One, 15:e0237302. https://doi.org/10.1371/journal.pone.0237302

16. Lei Q, Li G, Ma X, et al., 2021, Correlation between CT Findings and Outcomes in 46 Patients with Coronavirus Disease 2019. Sci Rep, 11:1103. https://doi.org/10.1038/s41598-020-79183-4

17. Dai H, Zhang X, Xia J, et al., 2020, High-Resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China. Int J Infect Dis, 95:106–12. https://doi.org/10.1016/j.ijid.2020.04.003

18. Shang YF, Liu T, Yu JN, et al., 2021, Half-Year Follow-Up of Patients Recovering from Severe COVID-19: Analysis of Symptoms and Their Risk Factors. J Intern Med, 290:444–50. https://doi.org/10.1111/joim.13284

19. Wolff D, Nee S, Hickey NS, et al., 2021, Risk Factors for Covid-19 Severity and Fatality: A Structured Literature Review. Infection, 49:15–28. https://doi.org/10.1007/s15010-020-01509-1

20. Bharat A, Querrey M, Markov NS, et al., 2020, Lung Transplantation for Patients with Severe COVID-19. Sci Transl Med, 12:eabe4282. https://doi.org/10.1126/scitranslmed.abe4282

21. Chen JY, Qiao K, Liu F, et al., 2020, Lung Transplantation as Therapeutic Option in Acute Respiratory Distress Syndrome for Coronavirus Disease 2019-Related Pulmonary Fibrosis. Chin Med J (Engl), 133:1390–6. https://doi.org/10.1097/CM9.0000000000000839

22. Ooi GC, Khong PL, Müller NL, et al., 2004, Severe Acute Respiratory Syndrome: Temporal Lung Changes at Thin-Section CT in 30 Patients. Radiology, 230:836–44. https://doi.org/10.1148/radiol.2303030853

23. Antonio GE, Wong KT, Chu WC, et al., 2003, Imaging in Severe Acute Respiratory Syndrome (SARS). Clin Radiol, 58:825–32. https://doi.org/10.1016/s0009-9260(03)00308-8

24. Das KM, Lee EY, Singh R, et al., 2017, Follow-up Chest Radiographic Findings in Patients with MERS-CoV after Recovery. Indian J Radiol Imaging, 27:342–9. https://doi.org/10.4103/ijri.IJRI_469_16

25. Lerner AM, Robinson DA, Yang L, et al., 2021, Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19. Ann Intern Med, 174:999–1003. https://doi.org/10.7326/M21-1043

26. Alharthy A, Abuhamdah M, Balhamar A, et al., 2021, Residual Lung Injury in Patients Recovering From COVID-19 Critical Illness: A Prospective Longitudinal Point-of-Care Lung Ultrasound Study. J Ultrasound Med, 40:1823–38. https://doi.org/10.1002/jum.15563

27. Zhang S, Bai W, Yue J, et al., 2021, Eight Months Follow-Up Study on Pulmonary Function, Lung Radiographic, and Related Physiological Characteristics in COVID-19 Survivors. Sci Rep, 11:13854. https://doi.org/10.1038/s41598-021-93191-y

28. Han X, Fan Y, Alwalid O, et al., 2021, Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19. Radiology, 301:210972. https://doi.org/10.1148/radiol.2021210972

29. Chen Y, Ding C, Yu L, et al., 2021, One-Year Follow-Up of Chest CT Findings in Patients after SARS-CoV-2 Infection. BMC Med, 19:191. https://doi.org/10.1186/s12916-021-02056-8

30. Cao J, Zheng X, Wei W, et al., 2021, Three-Month Outcomes of Recovered COVID-19 Patients: Prospective Observational Study. Ther Adv Respir Dis, 15:17534666211009410. https://doi.org/10.1177/17534666211009410

31. Liu C, Ye L, Xia R, et al., 2020, Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China. Ann Am Thorac Soc, 17:1231–7. https://doi.org/10.1513/AnnalsATS.202004-324OC.

32. Townsend L, Dowds J, O’Brien K, et al., 2021, Persistent Poor Health after COVID-19 is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am Thorac Soc, 18:997–1003. https://doi.org/10.1513/AnnalsATS.202009-1175OC

33. Recalde-Zamacona B, García-Tobar L, Argueta A, et al., 2020, Histopathological Findings in Fatal COVID-19 Severe Acute Respiratory Syndrome: Preliminary Experience from a Series of 10 Spanish Patients. Thorax, 75:1116–8. https://doi.org/10.1136/thoraxjnl-2020-215577

34. Xu Z, Shi L, Wang Y, et al., 2020, Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. Lancet Respir Med, 8:420–2. https://doi.org/10.1016/S2213-2600(20)30076-X

35. Barton LM, Duval EJ, Stroberg E, et al., 2020, COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol, 153:725–33. https://doi.org/10.1093/ajcp/aqaa062

36. Angirish B, Parmar K, 2020, Lung Cavitation-A Rare Complication in COVID-19 Patients: A Case Report. Arch Pulmonol Respir Care, 6:78–80. https://doi.org/10.17352/aprc.000061

37. Chen Y, Chen W, Zhou J, et al., 2021, Large Pulmonary Cavity in COVID-19 Cured Patient Case Report. Ann Palliat Med, 10:5786–91. https://doi.org/10.21037/apm-20-452

38. Amaral LT, Beraldo GL, Brito VM, et al., 2020, Lung Cavitation in COVID-19: Co-Infection Complication or Rare Evolution? Einstein (Sao Paulo), 18:eA15822. https://doi.org/10.31744/einstein_journal/2020ai5822

39. Marchiori E, Nobre LF, Hochhegger B, et al., 2021, Pulmonary Cavitation in Patients with COVID-19. Clin Imaging, 88:78–9. https://doi.org/10.1016/j.clinimag.2021.04.038

40. Selvaraj V, 2021, Pulmonary Cavitation : A Rare Complication of COVID-19 Pneumonia. Med Rep Case Stud, 6:196.

41. Erok B, Kibici K, Atca AO, 2020, Pulmonary Cavitation in COVID-19 Pneumonia: Is it Primary or Secondary? Afr J Respir Med, 15:16–7.

42. Kumar A, Gupta RK, Layek A, et al., 2021, Pulmonary Cavitation Post-COVID-19 Pneumonia : A Case Report. Ann Clin Med Res, 2:1035.

43. Jafari R, Cegolon L, Masghsoudi H, et al., 2021, Simultaneous Giant Cavity Pulmonary Lesion and Pneumothorax Following COVID-19 Pneumonia. Radiol Case Rep, 16:2534–6. https://doi.org/10.1016/j.radcr.2021.06.026

44. Wu C, Chen X, Cai Y, et al., 2020, Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 180:934–43. https://doi.org/10.1001/jamainternmed.2020.0994

45. Liu X, Zhou H, Zhou Y, et al., 2020, Risk Factors Associated with Disease Severity and Length of Hospital Stay in  COVID-19 Patients. J Infect, 81:e95–7. https://doi.org/10.1016/j.jinf.2020.04.008

46. George PM, Wells AU, Jenkins RG, 2020, Pulmonary Fibrosis and COVID-19: The Potential Role for Antifibrotic Therapy. Lancet Respir Med, 8:807–15. https://doi.org/10.1016/S2213-2600(20)30225-3

47. Nalbandian A, Sehgal K, Gupta A, et al., 2021, Post-Acute COVID-19 Syndrome. Nat Med, 27:601–15. https://doi.org/10.1038/s41591-021-01283-z

48. Huang C, Huang L, Wang Y, et al., 2021, 6-Month Consequences of COVID-19 in Patients Discharged from Hospital: A Cohort Study. Lancet, 397:220–32. https://doi.org/10.1016/S0140-6736(20)32656-8

49. Arnold DT, Hamilton FW, Milne A, et al., 2021, Patient Outcomes after Hospitalisation with COVID-19 and Implications for Follow-up: Results from a Prospective UK Cohort. Thorax, 76:399–401. https://doi.org/10.1136/thoraxjnl-2020-216086

50. Ali RM, Ghonimy MB, 2021, Post-COVID-19 Pneumonia Lung Fibrosis: A Worrisome Sequelae in Surviving Patients. Egypt J Radiol Nucl Med, 52:101. https://doi.org/10.1186/s43055-021-00484-3

51. Zha L, Shen Y, Pan L, et al., 2021, Follow-Up Study on Pulmonary Function and Radiological Changes in Critically Ill Patients with COVID-19. J Infect, 82:159–98. https://doi.org/10.1016/j.jinf.2020.05.040

52. Salem AM, Al Khathlan N, Alharbi AF, et al., 2021, The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors. Int J Gen Med, 14:3271–80. https://doi.org/10.2147/IJGM.S319436

53. Sokolowska M, Lukasik ZM, Agache I, et al., 2020, Immunology of COVID-19: Mechanisms, Clinical Outcome, Diagnostics, and Perspectives a Report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy, 75:2445–76. https://doi.org/10.1111/all.14462

54. Liu Z, Li X, Fan G, et al., 2021, Low-to-Moderate Dose Corticosteroids Treatment in Hospitalized Adults with COVID-19. Clin Microbiol Infect, 27:112–7. https://doi.org/10.1016/j.cmi.2020.09.045

55. Ou M, Zhu J, Ji P, et al., 2020, Risk Factors of Severe Cases with COVID-19: A Meta-Analysis. Epidemiol Infect, 148:e175. https://doi.org/10.1017/S095026882000179X

56. Wang D, Hu B, Hu C, et al., 2020, Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323:1061–9. https://doi.org/10.1001/jama.2020.1585

57. Zhang J, Wang X, Jia X, et al., 2020, Risk Factors for Disease Severity, Unimprovement, and Mortality in COVID-19 Patients in Wuhan, China. Clin Microbiol Infect, 26:767–72. https://doi.org/10.1016/j.cmi.2020.04.012

58. Ebinger JE, Achamallah N, Ji H, et al., 2020, Pre-Existing Traits Associated with Covid-19 Illness Severity. PLoS One, 15:e0236240. https://doi.org/10.1371/journal.pone.0236240

59. Du H, Dong X, Zhang JJ, et al., 2021, Clinical Characteristics of 182 Pediatric COVID-19 Patients with Different Severities and Allergic Status. Allergy, 76:510–32. https://doi.org/10.1111/all.14452

60. Bompard F, Monnier H, Saab I, et al., 2020, Pulmonary Embolism in Patients with COVID-19 Pneumonia. Eur Respir J, 56:17–20. https://doi.org/10.1183/13993003.01365-2020

61. Liu J, Li S, Liu J, et al., 2020, Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients. EBioMedicine, 55:0102763. https://doi.org/10.1016/j.ebiom.2020.102763

62. d’Alessandro M, Cameli P, Refini RM, et al., 2020, Serum KL-6 Concentrations as a Novel Biomarker of Severe COVID-19. J Med Virol, 92:2216–20. https://doi.org/10.1002/jmv.26087

63. Rai DK, Sharma P, Kumar R, 2021, Post Covid 19 Pulmonary Fibrosis. Is it Real Threat? Indian J Tuberc, 68:330–3. https://doi.org/10.1016/j.ijtb.2020.11.003

64. Ojo AS, Balogun SA, Williams OT, et al, 2020, Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med, 2020:6175964. https://doi.org/10.1155/2020/6175964

65. Sohrabi C, Alsafi Z, O’Neill N, et al., 2020, World Health Organization Declares Global Emergency: A Review of the 2019 Novel Coronavirus (COVID-19). Int J Surg, 76:71–6. https://doi.org/10.1016/j.ijsu.2020.02.034

66. Chen N, Zhou M, Dong X, et al., 2020, Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet (London, England), 395:507–13. https://doi.org/10.1016/S0140-6736(20)30211-7

67. Opal SM, Girard TD, Ely EW, 2005, The Immunopathogenesis of Sepsis in Elderly Patients. Clin Infect Dis, 41:S504–12. https://doi.org/10.1086/432007

68. Chen R, Liang W, Jiang M, et al., 2020, Risk Factors of Fatal Outcome in Hospitalized Subjects with Coronavirus 
Disease 2019 From a Nationwide Analysis in China. Chest, 158:97–105. https://doi.org/10.1016/j.chest.2020.04.010

69. Yang X, Yu Y, Xu J, et al., 2020, Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational study. Lancet Respir Med, 8:475–81. https://doi.org/10.1016/S2213-2600(20)30079-5

70. Grasselli G, Zangrillo A, Zanella A, et al., 2020, Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 323:1574–81. https://doi.org/10.1001/jama.2020.5394

71. Hu L, Chen S, Fu Y, et al., 2020, Risk Factors Associated with Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China. Clin Infect Dis, 71:2089–98. https://doi.org/10.1093/cid/ciaa539

72. Zhang JJ, Dong X, Cao YY, et al., 2020, Clinical Characteristics of 140 Patients Infected with SARS-CoV-2 in Wuhan, China. Allergy, 75:1730–41. https://doi.org/10.1111/all.14238

73. Li X, Xu S, Yu M, et al., 2020, Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan. J Allergy Clin Immunol, 146:110–8. https://doi.org/10.1016/j.jaci.2020.04.006

74. Zheng Z, Peng F, Xu B, et al., 2020, Risk Factors of Critical and Mortal COVID-19 Cases: A Systematic Literature Review and Meta-Analysis. J Infect, 81:e16–25. https://doi.org/10.1016/j.jinf.2020.04.021

75. Riccardo F, Ajelli M, Andrianou XD, et al., 2020, Epidemiological Characteristics of COVID-19 Cases and Estimates of the Reproductive Numbers 1 Month into the Epidemic, Italy, 28 January to 31 March 2020. Euro Surveill, 25:2000790. https://doi.org/10.2807/1560-7917.ES.2020.25.49.2000790

76. Stokes EK, Zambrano LD, Anderson KN, et al., 2020, Coronavirus Disease 2019 Case Surveillance-United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep, 69:759–65. https://doi.org/10.15585/mmwr.mm6924e2

77. Cao M, Zhang D, Wang Y, et al., 2020, Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. medRxiv, 2020:2020.03.04.20030395. https://doi.org/10.1101/2020.03.04.20030395

78. Jin JM, Bai P, He W, et al., 2020, Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health, 8:152. https://doi.org/10.3389/fpubh.2020.00152

79. Memtsoudis SG, Ivascu NS, Pryor KO, et al., 2020, Obesity as a Risk Factor for Poor Outcome in Covid-19-Induced Lung Injury: The Potential Role of Undiagnosed Obstructive Sleep Apnoea. Br J Anaesth, 125:e262–3. https://doi.org/10.1016/j.bja.2020.04.078

80. Simonnet A, Chetboun M, Poissy J, et al., 2020, High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring), 28:1195–9. https://doi.org/10.1002/oby.22831

81. Guo W, Li M, Dong Y, et al., 2020, Diabetes is a Risk Factor for the Progression and Prognosis of COVID-19. Diabetes Metab Res Rev, 36:e3319. https://doi.org/10.1002/dmrr.3319

82. Rashedi J, Poor BM, Asgharzadeh V, et al., 2020, Risk Factors for COVID-19. Infez Med, 28:469–74.

83. Rajpal A, Rahimi L, Ismail-Beigi F, 2020, Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes. J Diabetes, 12:895–908. https://doi.org/10.1111/1753-0407.13085

84. Hayden MR, 2020, Endothelial Activation and Dysfunction in Metabolic Syndrome, Type 2 Diabetes and Coronavirus Disease 2019. J Int Med Res, 48:300060520939746. https://doi.org/10.1177/0300060520939746

85. Rubin SJ, Falkson SR, Degner NR, et al., 2021, Clinical Characteristics Associated with COVID-19 Severity in California. J Clin Transl Sci, 5:e3. https://doi.org/10.1017/cts.2020.40

86. Gao YD, Ding M, Dong X, et al., 2021, Risk Factors for Severe and Critically Ill COVID-19 Patients: A Review. Allergy, 76:428–55. https://doi.org/10.1111/all.14657

87. Liu Y, Du X, Chen J, et al., 2020, Neutrophil-to-Lymphocyte Ratio as an Independent Risk Factor for Mortality in Hospitalized Patients with COVID-19. J Infect, 81:e6–12. https://doi.org/10.1016/j.jinf.2020.04.002

88. Qu R, Ling Y, Zhang YH, et al., 2020, Platelet-to-Lymphocyte Ratio is Associated with Prognosis in Patients with Coronavirus Disease-19. J Med Virol, 92:1533–41. https://doi.org/10.1016/j.jinf.2020.04.002

89. Liu Y, Sun W, Guo Y, et al., 2020, Association between Platelet Parameters and Mortality in Coronavirus Disease 2019: Retrospective Cohort Study. Platelets, 31:490–6. https://doi.org/10.1080/09537104.2020.1754383

90. Gao L, Jiang D, Wen XS, et al., 2020, Prognostic Value of NT-proBNP in Patients with Severe COVID-19. Respir Res, 21:83. https://doi.org/10.1186/s12931-020-01352-w

91. Yan L, Zhang HT, Goncalves J, et al., 2020, An Interpretable Mortality Prediction Model for COVID-19 Patients. Nat Mach Intell, 2:283–8. https://doi.org/10.1038/s42256-020-0180-7

92. Ye W, Chen G, Li X, et al., 2020, Dynamic Changes of D-Dimer and Neutrophil-Lymphocyte Count Ratio as Prognostic Biomarkers in COVID-19. Respir Res, 21:169. https://doi.org/10.1186/s12931-020-01428-7

93. Ng WL, Lee JM, Zhou M, et al., 2020, Vat Polymerization-Based Bioprinting-Process, Materials, Applications and Regulatory Challenges. Biofabrication, 12:022001. https://doi.org/10.1088/1758-5090/ab6034

94. Yu J, Park SA, Kim WD, et al., 2020, Current Advances in 3D Bioprinting Technology and Its Applications for Tissue Engineering. Polymers (Basel), 12:2958. https://doi.org/10.3390/polym12122958

95. Donderwinkel I, van Hest JC, Cameron NR, 2017, Bio-Inks for 3D Bioprinting: Recent Advances and Future Prospects. Polym Chem, 8:4451–71.

96. Tan B, Gan S, Wang X, et al., 2021, Applications of 3D Bioprinting in Tissue Engineering: Advantages, Deficiencies, Improvements, and Future Perspectives. J Mater Chem B, 9:5385–413.

97. Bishop ES, Mostafa S, Pakvasa M, et al., 2017, 3-D Bioprinting Technologies in Tissue Engineering and Regenerative Medicine: Current and Future Trends. Genes Dis, 4:185–95.

98. Cui H, Nowicki M, Fisher JP, et al., 2017, 3D Bioprinting for Organ Regeneration. Adv Healthc Mater, 6:1601118. https://doi.org/10.1002/adhm.201601118

99. Liu N, Ye X, Yao B, et al., 2021, Advances in 3D Bioprinting Technology for Cardiac Tissue Engineering and Regeneration. Bioact Mater, 6:1388–401. https://doi.org/10.1016/j.bioactmat.2020.10.021

100. Cui H, Miao S, Esworthy T, et al., 2018, 3D Bioprinting for Cardiovascular Regeneration and Pharmacology. Adv Drug Deliv Rev, 132:252–69. https://doi.org/10.1016/j.addr.2018.07.014

101. Ng WL, Ayi TC, Liu YC, et al., 2021, Fabrication and Characterization of 3D Bioprinted Triple-Layered Human Alveolar Lung Models. Int J Bioprint, 7:332. https://doi.org/10.18063/ijb.v7i2.332

102. Grigoryan B, Paulsen SJ, Corbett DC, et al., 2019, Multivascular Networks and Functional Intravascular Topologies within Biocompatible Hydrogels. Science, 364:458–64.

103. Dasgupta Q, Black LD, 2019, A Fresh Slate for 3D Bioprinting. Science, 365:446–7. https://doi.org/10.1126/science.aay0478

104. Alvarez-Aquino FG, Shah S, 2021, Lung Transplantation: Challenges in the COVID-19 Era, a Review of the Literature. Curr Challenges Thorac Surg, 3:29. https://doi.org/10.21037/ccts-20-172

105. Bery AI, Hachem RR, 2020, Antibody-Mediated Rejection after Lung Transplantation. Ann Transl Med, 8:411. https://doi.org/10.21037/atm.2019.11.86

106. Sun W, Starly B, Daly AC, et al., 2020, The Bioprinting Roadmap. Biofabrication, 12:022002. https://doi.org/10.1088/1758-5090/ab5158.

107. Kim IG, Park SA, Lee SH, et al., 2020, Transplantation of a 3D-Printed Tracheal Graft Combined with iPS Cell-Derived MSCs and Chondrocytes. Sci Rep, 10:4326. https://doi.org/10.1038/s41598-020-61405-4

108. Yasin R, Gouda W, 2020, Chest X-ray Findings Monitoring COVID-19 Disease Course and Severity. Egypt J Radiol Nucl Med, 51:193. https://doi.org/10.1186/s43055-020-00296-x

109. Daher A, Balfanz P, Cornelissen C, et al., 2020, Follow Up of Patients with Severe Coronavirus Disease 2019 (COVID-19): Pulmonary and Extrapulmonary Disease Sequelae. Respir Med, 174:106197. https://doi.org/10.1016/j.rmed.2020.106197

110. Zhao YM, Shang YM, Song WB, et al., 2020, Follow-Up Study of the Pulmonary Function and Related Physiological Characteristics of COVID-19 Survivors Three Months After Recovery. EClinical Medicine, 25:100463. https://doi.org/10.1016/j.eclinm.2020.100463.

111. Pulmonary Function Tests. Baltimore, Maryland: Johns Hopkins Medicine; 2022. Available from: https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/pulmonary-function-tests [Last accessed on 2022 May 15].

112. Solomon JJ, Heyman B, Ko JP, et al., 2021, CT of Post-Acute Lung Complications of COVID-19. Radiology, 301:E383–95. https://doi.org/10.1148/radiol.2021211396

113. Pang B, Li H, Liu Q, et al., 2021, CT Quantification of COVID-19 Pneumonia at Admission Can Predict Progression to Critical Illness: A Retrospective Multicenter Cohort Study. Front Med, 8:689568. https://doi.org/10.3389/fmed.2021.689568

114. Raghu G, Wilson KC, 2020, COVID-19 Interstitial Pneumonia: Monitoring the Clinical Course in Survivors. Lancet Respir Med, 8:839–42. https://doi.org/10.1016/S2213-2600(20)30349-0

115. Humphries SM, Yagihashi K, Huckleberry J, et al., 2017, Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up. Radiology, 285:270–8. https://doi.org/10.1148/radiol.2017161177

116. Peng S, Chen J, Zhang W, et al., 2021, The Role of Chest CT Quantitative Pulmonary Inflammatory Index in the Evaluation of the Course and Treatment Outcome of COVID-19 Pneumonia. Sci Rep, 11:7752. https://doi.org/10.1038/s41598-021-87430-5.

117. Zou JN, Sun L, Wang BR, et al., 2021, The Characteristics and Evolution of Pulmonary Fibrosis in COVID-19 Patients as Assessed by AI-Assisted Chest HRCT. PLoS One, 16:e0248957. https://doi.org/10.1371/journal.pone.0248957

118. Xue M, Zhang T, Chen H, et al., 2021, Krebs Von den Lungen-6 as a Predictive Indicator for the Risk of Secondary Pulmonary Fibrosis and its Reversibility in COVID-19 Patients. Int J Biol Sci, 17:1565–73.

119. Deng K, Fan Q, Yang Y, et al., 2021, Prognostic Roles of KL-6 in Disease Severity and Lung Injury in COVID-19 Patients: A Longitudinal Retrospective Analysis. J Med Virol, 93:2505–12. https://doi.org/10.1002/jmv.26793

Share
Back to top
International Journal of Bioprinting, Electronic ISSN: 2424-8002 Print ISSN: 2424-7723, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept